Jim Cramer is reportedly optimistic about Johnson & Johnson (JNJ), citing its cancer drug portfolio and orthopedic spinoff as key factors. The company’s shares have seen significant growth, and analysts from RBC Capital and Bank of America have raised their price targets. Johnson & Johnson reported robust revenue growth in 2025 with further increases projected for 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Johnson & Johnson (JNJ) Is Amazing, Says Jim Cramer
Jim Cramer is reportedly optimistic about Johnson & Johnson (JNJ), citing its cancer drug portfolio and orthopedic spinoff as key factors. The company’s shares have seen significant growth, and analysts from RBC Capital and Bank of America have raised their price targets. Johnson & Johnson reported robust revenue growth in 2025 with further increases projected for 2026.